immunoglobulin H-gamma1_L-kappa, anti-[Homo sapiens CD47 (CD47 molecule, integrin associated protein, IAP, MER6, OA3) and anti-[Homo sapiens DLL3 (delta-like ligand 3, delta like canonical Notch ligand 3)], bispecific;
Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
Phanes Therapeuticsmonoclonal_antibodyPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 89/ 100
Competitive context
7 Active assets in the Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
[212pb]pb-mp0712 Molecular Partners AG | Phase 1/2 | CC |
Carboplatin Phanes Therapeutics | Phase 1/2 | CC |
[203Pb]Pb-MP0712 Molecular Partners AG | Phase 1/2 | CC |
ETOPOSIDE Phanes Therapeutics | Phase 1/2 | CC |
Peluntamig Phanes Therapeutics | Phase 1/2 | CC |
Atezolizumab Phanes Therapeutics | Phase 1/2 | CC |
ML261 Moonlight Bio, Inc | Phase 1 | CC |
Same molecule, other indications
immunoglobulin H-gamma1_L-kappa, anti-[Homo sapiens CD47 (CD47 molecule, integrin associated protein, IAP, MER6, OA3) and anti-[Homo sapiens DLL3 (delta-like ligand 3, delta like canonical Notch ligand 3)], bispecific; is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →